期刊
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
卷 117, 期 23, 页码 13012-13022出版社
NATL ACAD SCIENCES
DOI: 10.1073/pnas.1918845117
关键词
metastatic colorectal cancer; KRAS mutation; metformin; multidrug and toxic compound extrusion 1 (MATE1); DNA methyltransferase 1 (DNMT1)
资金
- National Nature Science Foundation of China [81770808, 81872165, 81701414, 81871211]
- National Key R&D Program of China [2018YFA0800403]
- Guangdong Provincial Key RD Program [2018B030337001, 2019B020227003]
- Key Project of Nature Science Foundation of Guangdong Province, China [2019B1515120077]
- Guangdong Natural Science Fund [2019A1515011810]
- Guangdong Science Technology Project [2017A020215075]
- Key Sci-Tech Research Project of Guangzhou Municipality, China [201803010017, 201807010069, 202002020022]
- 2017 and 2019 Milstein Medical Asian American Partnership Foundation Research Project Award in Translational Medicine
- China Postdoctoral Science Foundation [2019M 662991]
Metastatic colorectal cancer (mCRC) patients have poor overall survival despite using irinotecan- or oxaliplatin-based chemotherapy combined with anti-EGFR (epidermal growth factor receptor) drugs, especially those with the oncogene mutation of KRAS. Metformin has been reported as a potentially novel antitumor agent in many experiments, but its therapeutic activity is discrepant and controversial so far. Inspiringly, the median survival time for KRAS-mutation mCRC patients with diabetes on metformin is 37.8 mo longer than those treated with other hypoglycemic drugs in combination with standard systemic therapy. In contrast, metformin could not improve the survival of mCRC patients with wild-type KRAS. Interestingly, metformin is preferentially accumulated in KRASmutation mCRC cells, but not wild-type ones, in both primary cell cultures and patient-derived xenografts, which is in agreement with its tremendous effect in KRAS-mutation mCRC. Mechanistically, the mutated KRAS oncoprotein hypermethylates and silences the expression of multidrug and toxic compound extrusion 1 (MATE1), a specific pump that expels metformin from the tumor cells by upregulating DNA methyltransferase 1 (DNMT1). Our findings provide evidence that KRAS-mutation mCRC patients benefit from metformin treatment and targeting MATE1 may provide a strategy to improve the anticancer response of metformin.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据